Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929577 | 0.85 | RIPK1 (0.32) | KMT2A | |
| SCHEMBL21721080 | 0.83 | — | — | |
| SCHEMBL10212108 | 0.77 | KMT2A (0.33) | KMT2A | |
| SCHEMBL18930688 | 0.76 | — | — | |
| SCHEMBL12740534 | 0.69 | LMNA (0.31) | — | |
| SCHEMBL21719794 | 0.67 | — | — | |
| SCHEMBL21721083 | 0.67 | — | — | |
| SCHEMBL21721070 | 0.67 | KMT2A (0.33) | KMT2A | |
| SCHEMBL19102468 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL5599415 | 0.67 | KMT2A (0.34) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20180127447-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH | 2018-05-10 | — | — | US | disclosed |
| US-9850268-B2 | Metathesis catalysts and methods thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| US-9701702-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160229877-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL SCIENCE FOUNDATION | 2016-08-11 | — | — | US | disclosed |
| US-20160194343-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-9206211-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140316088-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194343-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | INF2, AFF2, KRAS | KMT2A 141/4885 |
| US-20160229877-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | CYP51A1, SQLE, MOGAT2 | KMT2A 1125/4885 |
| US-20180127447-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | INF2, AFF2, KRAS | KMT2A 141/4885 |
| US-20140316088-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | CYP51A1, SQLE, MOGAT2 | KMT2A 1125/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | KMT2A 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.